Background: Beta-blocker therapy after acute myocardial infarction (MI) improves survival.
Beta-blocker doses used in clinical practice are often substantially lower than those used in …

Methods and Results: Of the total population of 13,104 consecutive AMI patients enrolled in
the KAMIR-NIH, the current study analyzed 11,909 patients. These patients were classified …

Background Although long-term β-blocker therapy has been found beneficial in patients
after an acute myocardial infarction, these drugs are greatly underused by clinicians …

Background Long-term administration of beta-adrenergic blockers to patients after
myocardial infarction improves survival. However, physicians are reluctant to administer …

Beta‐blockers are recommended as standard of care for patients who experience a
myocardial infarction (MI). However, evidence to support this recommendation is primarily …

Background Debate exists about the efficacy of β-blockers in myocardial infarction and their
required duration of usage in contemporary practice. Methods We conducted a …

Objective: Acute myocardial infarction (AMI) remains a major cause of death and β-blockers
are known to reduce long-term mortality in post-AMI patients. We sought to determine …

BACKGROUND: Quality improvement programs have shown increased use of β-blockers
post–myocardial infarction (MI), but there are no data on whether appropriate doses are …

Although clinical guidelines recommend long-term β-blocker (BB) therapy to decrease
mortality after acute myocardial infarction, these recommendations are based predominantly …

Aims Most trials showing benefit of beta-blocker treatment after myocardial infarction (MI)
included patients with large MIs and are from an era before modern biomarker-based MI …